The ongoing Iran war and the disruption of shipping through the Strait of Hormuz have triggered one of the most significant shocks to global pharmaceutical supply chains in decades. For…
Indian pharmaceutical companies are executing a strategic pivot in 2026 — doubling down on specialty drugs and biosimilars through record-breaking M&A and US investment, while maintaining their core generics business…
The Indian pharmaceutical sector enters the second half of 2026 with significant momentum as three major developments converge: the India-UK Comprehensive Economic Trade Agreement (CETA) taking effect on July 15,…
India's pharmaceutical sector has entered the second half of 2026 on a strong footing, with exports rising 6.6% year-on-year and the Nifty Pharma index hitting an all-time high in early…